Literature DB >> 27226872

Hepatitis E Virus Infection Among Chronic Hemodialysis.

Shokouh Shayanpour1, Fatemeh Hayati1.   

Abstract

Entities:  

Keywords:  Chronic; Hemodialysis; Hepatitis E Virus

Year:  2016        PMID: 27226872      PMCID: PMC4877441          DOI: 10.5812/jjm.26645

Source DB:  PubMed          Journal:  Jundishapur J Microbiol        ISSN: 2008-3645            Impact factor:   0.747


× No keyword cloud information.
Dear Editor, Recently, we read with great interest the article by Beladi Mousavi et al. (1) entitled “epidemiology of hepatitis E virus infection in patients on chronic hemodialysis" you published in your most valuable journal. The author evaluated the prevalence of anti-HEV IgG antibody among chronic hemodialysis (HD) patients in Imam Khomeini hospital, Ahvaz city, in southwest Iran. The results of this study showed that the prevalence of anti-HEV IgG antibody among these patients is 10.63% without any significant difference due to HEV, age, gender and duration of HD or HCV antibody titer (1). The results of the study are interesting. According to the article, HEV infection is endemic in Khuzestan province, Iran (1). We think that the results of the study are limited by the small number of patients (47 HD patients) enrolled in the study. A multicenter evaluation with a large number of patients is needed for a better estimation of the prevalence of HEV infection among dialysis patients. End stage renal disease (ESRD) is a life-threatening disease with significant complications found in people around the world. In contrast to hepatitis B and C, which are associated with significant mortality among these patients, hepatitis E had been believed to be a self-limited acute infection with spontaneous recovery in almost all cases and without any association with chronic hepatitis (2-7). However, some recent studies have reported several cases of persistent HEV-related chronic hepatitis and its relatively rapid evolution to HEV-related cirrhosis, especially among immunosuppressive patients, including organ transplant recipients (8, 9). For example, Kamar et al. (10) evaluated 241 renal allograft recipients and demonstrated that HEV infection could develop into a chronic active hepatitis in nearly 60% of renal transplant patients who had HEV infection. In addition, although transmission of HEV primarily occurs by the fecal-oral route, some studies have indicated that other modes of transmission such as mother-to-child, parenteral routes, transfusion and HD could potentially play a role in the transmission of HEV. It has also been suggested that the fecal-oral route may also be a pathway for HEV transmission in HD centers (8-10). Due to the to the possibility of HEV transmission in HD centers and the possibility of persistent HEV-related chronic hepatitis and HEV-related cirrhosis, we agree with Beladi Mousavi et al. on the periodic monitoring of HD patients. In this case, careful observation is needed for the diagnosis of HEV infection, especially among ESRD patients who are candidates for kidney transplantation.
  10 in total

Review 1.  Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis.

Authors:  F Fabrizi; P Martin; V Dixit; S Bunnapradist; G Dulai
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

2.  Evaluation of acquired cystic kidney disease in patients on hemodialysis with ultrasonography.

Authors:  Seyed Seifollah Beladi Mousavi; Moshgan Sametzadeh; Fatemeh Hayati; Seyed Mahmoud Fatemi
Journal:  Iran J Kidney Dis       Date:  2010-07       Impact factor: 0.892

3.  Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.

Authors:  Amir Feily; Benafshe Dormanesh; Ali Reza Ghorbani; Zahra Moosavi; Maryam Kouchak; Bahman Cheraghian; Seyed Seifollah Beladi Mousavi; Abolfath Mehrabian; Nastaran Ranjbari
Journal:  Int J Clin Pharmacol Ther       Date:  2012-07       Impact factor: 1.366

4.  Long-term survival of patients with end-stage renal disease on maintenance hemodialysis: a multicenter study in Iran.

Authors:  Seyed Seifollah Beladi-Mousavi; Mohammad Javad Alemzadeh-Ansari; Mohammad Hasan Alemzadeh-Ansari; Marzieh Beladi-Mousavi
Journal:  Iran J Kidney Dis       Date:  2012-11       Impact factor: 0.892

5.  Effect of intranasal DDAVP in prevention of hypotension during hemodialysis.

Authors:  Seyed S Beladi-Mousavi; Marzieh Beladi-Mousavi; Fatemeh Hayati; Mehdi Talebzadeh
Journal:  Nefrologia       Date:  2012       Impact factor: 2.033

6.  Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better.

Authors:  Gerald DaRoza; Andrea Loewen; Ognjenka Djurdjev; Janet Love; Cathy Kempston; Shelley Burnett; Mercedeh Kiaii; Paul A Taylor; Adeera Levin
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

7.  Hepatitis E virus and chronic hepatitis in organ-transplant recipients.

Authors:  Nassim Kamar; Janick Selves; Jean-Michel Mansuy; Leila Ouezzani; Jean-Marie Péron; Joëlle Guitard; Olivier Cointault; Laure Esposito; Florence Abravanel; Marie Danjoux; Dominique Durand; Jean-Pierre Vinel; Jacques Izopet; Lionel Rostaing
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

8.  Health-related quality of life in hemodialysis patients: an Iranian multi-center study.

Authors:  Zohreh Rostami; Behzad Einollahi; Mahboob Lessan-Pezeshki; Azam Soleimani Najaf Abadi; Susan Mohammadi Kebar; Heshmatollah Shahbazian; Atieh Makhlough; Khadijeh Makhdoomi; Mahmood Salesi; Mojgan Jalalzadeh
Journal:  Nephrourol Mon       Date:  2013-08-18

9.  Epidemiology of hepatitis e virus infection in patients on chronic hemodialysis.

Authors:  Seyed Seifollah Beladi Mousavi; Farzad Motemednia; Marzieh Beladi Mousavi
Journal:  Jundishapur J Microbiol       Date:  2014-05-01       Impact factor: 0.747

10.  A Better Quality of Life in Hemodialysis Patients With Viral Hepatitis: Is it a Reality?

Authors:  Eghlim Nemati; Mohsen Motalebi
Journal:  Hepat Mon       Date:  2013-11-30       Impact factor: 0.660

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.